

Test results of New Psychoactive Substances

Unit : Number of cases (Percentage)

Ranking Year	1	2	3	4	5
2017	Mephedrone 25,612 cases (19.49%)	Ketamine 21,429 cases (16.31%)	CMC 9,283 cases (7.06%)	N-Ethylpentylone 6,457 cases (4.91%)	5-MeO-MIPT 4,010 cases (3.05%)
2018	MEAPP 21,304 cases (15.71%)	Ketamine 21,044 cases (15.52%)	4-CEC 19,198 cases (14.16%)	Mephedrone 17,638 cases (13.01%)	N-Ethylpentylone 12,295 cases (9.07%)
2019	Mephedrone 68,579 cases (43.48%)	Ketamine 18,291 cases (11.6%)	Methyl-α- ethylaminopentiophenone 10,258 cases (6.5%)	4-CEC 9,587 cases (6.08%)	N-Ethylpentylone 9,140 cases (5.79%)
2020	Mephedrone 213,941 cases (53.71%)	Eutylone 59,047 cases (14.82%)	4-MDMC 56,666 cases (14.23%)	Ketamine 14,821 cases (3.72%)	Phenazepam 7,918 cases (1.99%)
2021	Mephedrone 152,401 cases (51.49%)	4-MDMC 91,492 cases (30.91%)	Ketamine 17,221 cases (5.82%)	Eutylone 11,448 cases (3.87%)	N-Ethylpentylone 5,035 cases (1.70%)
2022	Mephedrone 124,242 cases (49.87%)	4-MDMC 59,413 cases (23.84%)	Ketamine 23,353 cases (9.37%)	bk-MDMA 7,744 cases (3.10%)	Eutylone 6,368 cases (2.55%)
2023	Mephedrone 238,409 cases (52.88%)	4-MDMC 154,759 cases (34.32%)	Ketamine 24,520 cases (5.44%)	CMC 6,721 cases (1.49%)	Sibutramine 5,071 cases (1.12%)
Jan 2024	Mephedrone 28,109 cases (49.66%)	4-MDMC 24,863 cases (43.92%)	Ketamine 2,072 cases (3.66%)	CMC 661 cases (1.17%)	α-PiHP 218 cases (0.39%)

Source: Urine Test for Drug Abuse Reporting System